Loading...
Market
What will be Pfizer's RSV vaccine, Abrysvo, sales revenue in the first year of commercial availability by December 31, 2025?
3
Resolution / Starting Odds
Less than $500 million • 25%
$500 million to $1 billion • 25%
$1 billion to $1.5 billion • 25%
More than $1.5 billion • 25%
Pfizer's financial reports and earnings announcements
Story
Pfizer's RSV Vaccine Shows Positive Results in Immunocompromised Adults
Aug 16, 2024, 11:00 AM
Pfizer has announced positive results from a trial of its RSV vaccine, Abrysvo, which demonstrated a strong immune response in immunocompromised adults. The late-stage trial involved four groups of adults aged 18 and older with compromised immune systems, including those on dialysis, with lung cancer, on immunotherapy, and who had received solid-organ transplants. The vaccine generated robust antibodies against RSV-A and RSV-B, showcasing its potential in protecting at-risk adults from severe RSV-related illnesses. This development is part of Pfizer's efforts to expand the reach of its RSV vaccine.
View original story
Similar markets
Less than $500 million • 25%
$500 million to $1 billion • 25%
$1 billion to $1.5 billion • 25%
More than $1.5 billion • 25%
Less than 20% • 25%
20% to 40% • 25%
40% to 60% • 25%
More than 60% • 25%
Less than 1 million • 25%
1-3 million • 25%
3-5 million • 25%
More than 5 million • 25%
Yes • 50%
No • 50%
Less than 1 million • 25%
1 million to 3 million • 25%
3 million to 5 million • 25%
More than 5 million • 25%
Yes • 50%
No • 50%
Decrease by less than 10% • 25%
Decrease by 10% to 20% • 25%
Decrease by 20% to 30% • 25%
Decrease by more than 30% • 25%
Less than $500 million • 25%
$500 million to $1 billion • 25%
$1 billion to $1.5 billion • 25%
More than $1.5 billion • 25%
Yes • 50%
No • 50%